Corona Remedies Ltd
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
- Market Cap ₹ 10,951 Cr.
- Current Price ₹ 1,790
- High / Low ₹ 1,951 / 1,337
- Stock P/E 55.0
- Book Value ₹ 122
- Dividend Yield 0.57 %
- ROCE 33.2 %
- ROE 29.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 23.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
Cons
- Stock is trading at 14.6 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 | |
| 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,110 | |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 293 |
| OPM % | 13% | 15% | 18% | 3% | 14% | 15% | 20% | 21% |
| 3 | 3 | 5 | 7 | 7 | 5 | 5 | -8 | |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 | 118 | 198 | 240 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% | 23% |
| 35 | 59 | 70 | -0 | 85 | 90 | 149 | 185 | |
| EPS in Rs | 74.85 | 126.70 | 150.72 | -0.08 | 13.85 | 14.80 | 24.37 | 30.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 17% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 33% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 26% |
| Last Year: | 30% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 685 |
| 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 | |
| 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 | |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 | |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 | 25 |
| 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 | |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 | |
| -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 | |
| 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 | |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 55 |
| CFO/OP | 49% | 65% | 101% | 557% | 100% | 112% | 97% | 95% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 | 38 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 | 175 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 | 7 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 | -15 |
| ROCE % | 30% | 27% | 1% | 29% | 25% | 31% | 33% |
Insights
In beta| Mar 2023 | Mar 2024 | Jun 2025 | |
|---|---|---|---|
| Actual Production - Total (Tablets/Capsules) Million Units |
|
||
| Capacity Utilization - Bhayla Tablets/Capsules Percentage |
|||
| Chronic Segment Contribution to Revenue Percentage |
|||
| Installed Capacity - Tablets/Capsules (Total) Million Units |
|||
| IPM Market Rank Rank |
|||
| Market Share in Total IPM Percentage |
|||
| Number of Medical Representatives Number |
|||
| Number of Brands with Sales > INR 10 Crores Number |
|||
| Number of Distributors Number |
|||
Extracted by Screener AI
Documents
Announcements
-
Annual Secretarial Compliance Report For The Financial Year Ended March 31 2026
1d - Annual Secretarial Compliance Report for FY ended March 31, 2026 filed; no non-compliances observed.
-
Annual Secretarial Compliance Report For The Financial Year Ended March 31 2026
1d - Annual secretarial compliance report for FY26 confirms statutory compliance.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
1d - Audio recording of Q4 and FY26 analyst/investor conference call is now available online.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Corona Remedies published audited standalone and consolidated Q4 and FY2026 results on May 12, 2026.
- Announcement under Regulation 30 (LODR)-Investor Presentation 2d
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT
-
Jan 2026Transcript PPT REC